Update of antispike severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) monoclonal antibodies
By: Chatterjee, Suparna
.
Contributor(s): Choudhury, Shouvik.
Publisher: Mumbai Wolter Kluwer 2022Edition: Vol.54(1), Jan-Feb.Description: 51-57p.Subject(s): PHARMACOLOGYOnline resources: Click here
In:
Indian Journal of PharmacologySummary: The use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer
therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases
such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike
SARS‑CoV‑2 monoclonal antibody cocktails (casirivimab with imdevimab and bamlanivimab with
etesevimab) and single agent sotrovimab have received emergency use authorization for treatment of
nonhospitalized COVID‑19 patients with mild‑to‑moderate disease at high risk of disease progression.
This review summarizes their mechanism of action, salient pharmacokinetic profile, safety and clinical
trial (ongoing and completed) data. Despite evidence to support its use for the indication, the high
cost of these biologics may make it unaffordable for many patients, but further clinical studies on
their cost‑benefit profile shall provide useful information to the scientific community and patients.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2022-2152 |
The use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer
therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases
such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike
SARS‑CoV‑2 monoclonal antibody cocktails (casirivimab with imdevimab and bamlanivimab with
etesevimab) and single agent sotrovimab have received emergency use authorization for treatment of
nonhospitalized COVID‑19 patients with mild‑to‑moderate disease at high risk of disease progression.
This review summarizes their mechanism of action, salient pharmacokinetic profile, safety and clinical
trial (ongoing and completed) data. Despite evidence to support its use for the indication, the high
cost of these biologics may make it unaffordable for many patients, but further clinical studies on
their cost‑benefit profile shall provide useful information to the scientific community and patients.
Click on an image to view it in the image viewer
There are no comments for this item.